An undergarment article has a fabric a fabric layer for wearing about a pelvic region of a person, a water-repellent layer coupled to a crotch portion of the fabric layer to form an inner chamber, and an inner pad disposed within the inner chamber between the water-repellent layer and the fabric layer. The inner pad is resistant to heat and includes a liquid-absorbent layer and a waterproof layer. The liquid-absorbent layer contacts the water-repellent layer and is effective for absorbing a volume of liquid greater than 2 fluid ounces. The waterproof layer is effective for restricting liquid from reaching the fabric layer. The crotch portion of the fabric layer and the water-repellent layer can be substantially elastic in at least one of a lateral direction and a longitudinal direction of the crotch portion. Methods for using the undergarment, kits and uses of the undergarment are also disclosed.

Various embodiments disclosed relate to a lubricant. The lubricant includes a first non-amphiphilic triglyceride. The lubricant further includes a second non-amphiphilic triglyceride. The second non-amphiphilic triglyceride is different from the first non-amphiphilic triglyceride. The lubricant further includes a non-amphiphilic glycol ester.

An apoptosis-mimicking structure includes a polymeric core. The polymeric core includes a polymer backbone. The polymer backbone includes or is modified with a functional group to directly or indirectly bond to an eat me signaling molecule. An eat me signaling molecule is bonded directly or indirectly to the functional group. Other structures include a scaffold and the apoptosis-mimicking structure immobilized on or incorporated into the scaffold.

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided.

Farnesol analogs, along with their related products (e.g., treatment compositions, wipes, absorbent articles, etc.) and their methods of formation, are provided. The farnesol analog includes a hydrophilic end group (e.g., a hydroxyl end group or a carboxylic acid end group) attached to farnesol via a covalent linkage (e.g., an ester group or an ether group).

The present invention provides a biological fiber composite dressing. The biological fiber composite dressing includes: a cloth membrane having a first surface layer and an opposing second surface layer, wherein the cloth membrane has cloth membrane fibers; and a biological fiber membrane having a third surface layer and an opposing fourth surface layer, wherein the biological fiber membrane is formed by bacteria of the genus Gluconacetobacter, and the fourth surface layer is combined with the first surface layer, and a plurality of biological fibers being wound and combined with the cloth membrane fibers are extended along the fourth surface layer of the biological fiber membrane, such that the moisturizing effect of the dressing can be enhanced by the biological fiber membrane, thereby carrying more active ingredients.

Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.

The present invention provides a pharmaceutical composition for the lubrication of joints, the pharmaceutical composition comprising a non-ionic tonicity agent comprising a polyol, and liposomes comprising at least one membrane comprising at least one phospholipid (PL) selected from a glycerophospholipid (GPL), said GPL having two C12-C18 hydrocarbon chains, being the same or different, and sphingomyelin (SM) having a C12-C18 hydrocarbon chain, the pharmaceutical composition being essentially free of an additional pharmaceutically active agent, wherein the at least one membrane has a phase transition temperature in the range of about 20 C. to about 39 C. and the joint has a joint temperature which is above the phase transition temperature.

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium.